The value of blood medication analysis to medication verification and reconciliation in older adults at the emergency department

The value of blood medication analysis to medication verification and reconciliation in older adults at the emergency department - MANATEE

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON57030

Enrollment

100

Registered

2024-08-19

Start date

2024-09-20

Completion date

Unknown

Last updated

2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

65-plussers met (verdenking op) polyfarmacie die op de SEH komen voor de interne geneeskunde Medication reconciliation medications found in blood

Interventions

None listed

Eligibility

Age

65 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Patient is 65 years or older. • Patient visits the emergency department of Amsterdam UMC, location AMC, for the internal medicine specialty or for another medicine specialty but is subsequentially admitted for the internal medicine specialty.and is then subsequentially admitted for the internal medicine specialty. • Patients use five or more prescribed medications, or are suspected of using five or more prescribed medications as determined by the treating physician at the emergency department. The medications must have a systemic effect, with at least 10% availability in the systemic circulation. Supplements are excluded. • Competent individuals can only participate if they wish to be informed about incidental relevant findings regarding their health from the analysis.

Exclusion criteria

Exclusion criteria: Patients are excluded if no medication verification was performed by the pharmacy team due to reasons such as personnel shortage. Note: patients are eligible for inclusion if medication verification could not be performed because the patient or representatives were not available at time of admission, i.e. due to severe illness, confusion etc.

Design outcomes

Primary

Measure	Time frame
The aim of this study is to explore the value and applicability of LC/MS/MS analysis in older adults with (suspected) polypharmacy at the ED. We will determine the agreement between the LC/MS/MS and the results of the medication verification team in older adults visiting the ED with (suspected) polypharmacy. Reasons for discrepancies will be explored. Furthermore we will retrospectively determine the impact the LC/MS/MS results could have had on the diagnostic process and treatment policy.	—

Measure

Time frame

The aim of this study is to explore the value and applicability of LC/MS/MS analysis in older adults with (suspected) polypharmacy at the ED. We will determine the agreement between the LC/MS/MS and the results of the medication verification team in older adults visiting the ED with (suspected) polypharmacy. Reasons for discrepancies will be explored. Furthermore we will retrospectively determine the impact the LC/MS/MS results could have had on the diagnostic process and treatment policy.

—

Secondary

Measure	Time frame
Estimation of patient groups with a high risk of medication discrepencies (with potential relevant impact on diagnostic process and treatment policy).	—

Countries

Netherlands

Outcome results